Biopharmaceuticals Contract Manufacturing Market by Product (Biologics, Biosimilar), Source (Mammalian, Non-Mammalian), Services, Scale of Operation, Therapeutic Applications - Global Forecast 2024-2030

Biopharmaceuticals Contract Manufacturing Market by Product (Biologics, Biosimilar), Source (Mammalian, Non-Mammalian), Services, Scale of Operation, Therapeutic Applications - Global Forecast 2024-2030

The Biopharmaceuticals Contract Manufacturing Market size was estimated at USD 18.27 billion in 2023 and expected to reach USD 19.16 billion in 2024, at a CAGR 5.14% to reach USD 25.95 billion by 2030.

Biopharmaceutical contract manufacturing is the outsourcing of biopharmaceutical production processes to third-party manufacturers. These specialized entities possess the expertise, equipment, and facilities required to manufacture biopharmaceutical products, which include vaccines, monoclonal antibodies, recombinant proteins, and other biologically derived pharmaceuticals. This collaborative approach enables biopharmaceutical companies to leverage external capabilities and resources to enhance scalability, reduce costs, and accelerate the time to market for new therapies. The biopharmaceutical contract manufacturing market is driven by an increasing pipeline of biologic drugs, rising demand for biosimilars, and the complexity of biologic drug production processes. The need for specialized manufacturing capabilities, stringent regulatory requirements, and the desire to reduce costs and time-to-market push pharmaceutical companies toward outsourcing. However, the high price of setting up a production facility for biopharmaceuticals may hinder market growth. Nevertheless, rising investments in biopharmaceutical R&D and manufacturing, coupled with a growing emphasis on personalized medicine globally, are expected to create potential opportunities for market growth.

Regional Insights

The Americas represent a significant market for biopharmaceuticals contract manufacturing, attributed to its advanced technological infrastructure, robust regulatory framework, and significant investments in biotech research. Recent initiatives focus on precision medicine and biologics, with numerous patents filed in bioprocessing and genetic engineering technologies. In addition, the emphasis on research in monoclonal antibodies and vaccines has attracted global contract manufacturing organizations (CMOs) to invest in the country. The biopharmaceutical contract manufacturing sector in Asia Pacific is booming, owing to the upgrading of manufacturing capabilities and enhancement of biologics production, with considerable investments in cell therapy and recombinant protein drugs. Furthermore, significant patents in bioreactor technologies and regenerative medicine and the focus on biosimilars and vaccines for domestic and international markets propel investments and collaborations, offering numerous opportunities for CMOs. The European Union exhibits growth in the biopharmaceuticals contract manufacturing market, supported by its advanced healthcare infrastructure and strong regulatory standards. Recent trends indicate a surge in biologics production and a growing interest in personalized medicines and cell therapies. Despite being nascent, the Middle East is gradually advancing in biopharmaceutical contract manufacturing, with investments focusing on vaccine production and biosimilars to address the rising healthcare needs. Africa's biopharmaceutical contract manufacturing is developing due to the region's focus on establishing local manufacturing capabilities to reduce dependency on imported drugs, emphasizing vaccines and common therapeutics.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Biopharmaceuticals Contract Manufacturing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Growing prevalence of chronic diseases
• Increasing number of CMOs and rising investments in advanced manufacturing technologies
• Rising outsourcing by biopharmaceutical companies

Market Restraints

• High price of setting up a production facility for biopharmaceuticals

Market Opportunities

• Increasing investments in biopharmaceutical R&D and manufacturing
• Growing emphasis on personalized medicine globally

Market Challenges

• Stringent regulatory requirements for CMOs

Market Segmentation Analysis

• Services: Proliferating utilization of analytical and QC studies critical for meeting regulatory standards
• Scale of Operation: Evolving commercial scale of operation for biopharmaceuticals contract manufacturing

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biopharmaceuticals Contract Manufacturing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biopharmaceuticals Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

SwiftPharma and PlantForm Corporation target blockbuster cancer drug with new contract manufacturing agreement for plant-made biosimilars

SwiftPharma joined forces with Canadian biopharmaceutical innovator PlantForm Corporation through a pivotal contract manufacturing arrangement. This collaboration is poised to revolutionize the production of antibodies and proteins by leveraging SwiftPharma's advanced manufacturing capabilities to synthesize biosimilar pembrolizumab, utilizing PlantForm's cutting-edge proprietary technology.

Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb

Samsung Biologics solidified its strategic alliance with global biopharma giant Bristol Myers Squibb through a newly announced agreement for the large-scale production of an antibody cancer drug substance. Under this collaboration, Samsung Biologics utilizes its state-of-the-art biomanufacturing facility, Plant 4, situated in Songdo, South Korea, to manufacture the drug substance for Bristol Myers Squibb.

Hikma and SK Biopharmaceuticals enter a strategic partnership

Hikma Pharmaceuticals PLC entered into a significant strategic partnership and exclusive licensing deal with SK Biopharmaceuticals to grant Hikma exclusive rights to commercialize and manufacture SK Biopharmaceuticals' innovative product lineup, including the groundbreaking anti-seizure medication, carbamate, across 17 countries within the Middle East & North Africa (MENA) region.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biopharmaceuticals Contract Manufacturing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceuticals Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include 3P Biopharmaceuticals, AbbVie, Inc., Aenova Group GmbH, AGC Biologics, Ajinomoto Co., Inc., Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Celonic AG, FUJIFILM Diosynth Biotechnologies, INCOG BioPharma Services, Inc., JRS PHARMA GmbH + Co. KG, KBI Biopharma Inc, Lonza AG, Merck KGaA, Pressure BioSciences, Inc. by Emergent Health Corp., ProBioGen AG, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific Inc., Toyobo Co., Ltd., and WuXi Biologics, Inc..

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
• Biologics
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Biosimilar
• Source
• Mammalian
• Non-Mammalian
• Services
• Analytical & QC studies
• Fill & Finish Operations
• Packaging
• Process Development
• Downstream
• Upstream
• Scale of Operation
• Clinical
• Commercial
• Therapeutic Applications
• Cardiovascular Diseases
• Infectious Disease
• Neurology
• Oncology
• Ophthalmology
• Respiratory Disorder

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year